Tech Company Financing Transactions
Glympse Bio Funding Round
Glympse Bio, based in Cambridge, secured $22 million in investment from Arch Venture Partners, Polaris Partners and CRV.
Transaction Overview
Company Name
Announced On
10/10/2018
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series A
Investors
Arch Venture Partners (Lead Investor)
Polaris Partners (Lead Investor) (Amy Schulman)
Proceeds Purpose
The proceeds of this round will be devoted to conducting clinical trials for its novel platform which uses bioengineered activity sensors to noninvasively detect human diseases and to monitor drug response.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
35 Cambridgepark Dr. 100
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
Glympse Bio is pioneering an in vivo sensing technology dedicated to transforming disease monitoring. The company has built a product engine enabling rapid development of tunable and bioengineered activity sensors for multiple indications including fibrosis, cancer, immunology and infectious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Caroline Loew
Chief Scientific Officer
Wendy Winckler
Co-Founder
Sangeeta Bhatia
Co-Founder
Gabe Kwong
VP - Bus. Development
Tracey Dawson
VP - Finance
Martha Denyer
VP - Operations
Dhaval Gosalia
Browse more venture capital transactions:
Prev: 10/10/2018: RevUp venture capital transaction
Next: 10/10/2018: ciValue venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs